Monday

25th Jul 2016

UK big pharma loses EU court battle over cheaper drugs

UK pharmaceutical firms have been defeated in their attempt to put an end to British government incentives to doctors to supply patients with cheaper but equivalent medicines.

The European Court of Justice rejected a complaint by the Association of the British Pharmaceutical Industry (ABPI) that such National Health Service (NHS) schemes were not an illegal inducement under EU law.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

  • UK health authorities are not seeking commercial advantage by the incentive scheme (Photo: Flickr)

In order to reduce public expenditure, the public health authorities in England and Wales introduced schemes providing doctors with financial incentives to prescribe cheap generic drugs rather than their more expensive patented counterparts.

A 2001 European directive relating to medicinal products prohibits "pecuniary advantages or benefits in kind" from being offered to doctors or pharmacists.

The bill aimed to prevent drug firms from offering incentives such as holidays, golf club memberships or other bonuses for prescribing their product, but in an attempted reversal of the legislation's original intention, the companies argued that rewards to medical practices acted in the same way.

But the court found that the directive was concerned primarily with the promotional activities carried out by the pharmaceutical industry and sought to prevent promotional practices that could push doctors to act more in line with their wallet than a patient's interest.

"By contrast, that prohibition does not apply to national public health authorities which ... do not pursue any profit-making or commercial aim," the court said in its ruling.

"Therefore, the financial incentive scheme examined, which forms part of such a policy, cannot be regarded as seeking the promotion of commercial promotion of medicinal products."

"No danger to public health can be established," the court concluded.

Investigation

ECB in ‘bail-out’ of scandal-tainted VW

The ECB has started to “bail out” Germany’s Volkswagen Group by buying its corporate bonds, but other EU-linked banks continue to shun the scandal-tainted firm.

Stakeholders' Highlights

  1. Belgrade Security ForumMigration, Security and Solidarity within Global Disorder: Academic Event 2016
  2. GoogleHow Google Fights Piracy: Creating Value While Fighting Piracy
  3. EJC"My Visit to Israel" - Opinion by MEP Lopez Aguilar, Chair of the EP Working Group on Antisemitism
  4. World VisionChildren Migrating, Out of School and at Work as Hunger Deepens in Southern Africa
  5. European Healthy Lifestyle AllianceStand-Up (and Exercise) to Prevent Chronic Diseases
  6. Centre Maurits CoppietersLaunches a Real-time News Hub Specialised in EU Stakeholders
  7. Dialogue PlatformFethullah Gulen Calls for International Probe Into Turkey Coup Allegations
  8. GoogleEU-US Privacy Shield: Restoring Faith in Data Flows and Transatlantic Relations
  9. World VisionWorld Leaders & Youth Advocates Launch Partnership to End Violence Vs. Children
  10. Counter BalanceReport: Institutionalised Corruption in Romania's Third Largest Company
  11. Access NowEuropol Supports Encryption. We Can Relax Now… Right?
  12. GoogleLearn about Google's projects across Europe on Twitter @GoogleBrussels